September 4, 2019 | Vensana in the News

New Medtech Investor Vensana Closes $225 Million Debut Fund

20

Novel FDA PMA & de novo 510k approvals

55

U.S. Commercial Product Launches

39

Level I Clinical Trials

29

Strategic Financings

30

Exits by IPO or M&A